JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

18 F-Fluorocholine PET/CT in primary hyperparathyroidism: superior diagnostic performance to conventional scintigraphic imaging for localization of hyperfunctioning parathyroid glands.

Journal of Nuclear Medicine 2019 September 28
Primary hyperparathyroidism (PHPT) is a common endocrine disorder, definitive treatment usually requiring surgical removal of the offending parathyroid glands. In order to perform focused surgical approaches, it is necessary to localize all hyperfunctioning glands. The aim of the study was to compare the efficiency of established conventional scintigraphic imaging modalities with emerging 18 F-Fluorocholine PET/CT imaging in preoperative localization of hyperfunctioning parathyroid glands in a larger series of PHPT patients. Methods: 103 patients with PHPT were imaged preoperatively with 18 F-Fluorocholine PET/CT and conventional scintigraphic imaging methods, consisting of 99m Tc-sestaMIBI SPECT/CT, 99m Tc-sestaMIBI/pertechnetate subtraction imaging and 99m Tc-sestaMIBI dual-phase imaging. The results of histological analysis as well as intact parathormone and serum calcium values obtained one day after surgery and on the follow-up served as the standard of truth for evaluation of imaging results. Results: Diagnostic performance of 18 F-Fluorocholine PET/CT surpassed conventional scintigraphic methods (separately or combined), with calculated sensitivity of 92% for PET/CT and 39-56% for conventional imaging (65% for conventional methods combined) in the entire patient group. Subgroup analysis, differentiating single and multiple hyperfunctioning parathyroid glands, showed PET/CT to be most valuable in multiple hyperfunctioning gland group with sensitivity of 88%, while conventional imaging with sensitivity of 22-34% (44% combined) was significantly inferior. Conclusion: 18 F-Fluorocholine PET/CT is the superior diagnostic modality in comparison to the conventional imaging methods, allowing for accurate preoperative localization in patients with PHPT.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app